Lifecare – New share capital registered

Reference is made to the stock exchange announcement by Lifecare AS (the "Company") published on 19 October 2023, announcing the successful completion of a private placement of 17,000,000 new shares in the Company, raising gross proceeds of NOK 42.5 million (the "Private Placement").

The share capital increase pertaining to the issuance of new shares in the Private Placement has been registered in the Norwegian Register of Business Enterprises, and the Company's new registered share capital is NOK 53,946,296.80 divided into 134,865,742 shares, each with a par value of NOK 0.40.

The delivery of shares to subscribers in the Private Placement was completed on 20 October 2023, pursuant to a share lending agreement between the Company, Carnegie AS (acting as bookrunner and manager in the Private Placement) and the Company’s major shareholder Teigland Eiendom AS. The new shares issued will be redelivered from Carnegie AS to Teigland Eiendom AS to settle the share lending agreement.

***
This information is subject to the disclosure requirements pursuant to Euronext Growth Oslo Rule Book II.

About us
Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body.